US market architecture for Paris luxury houses inside and around LVMH, Kering, Hermès, Chanel, and Dior, French biotech and pharma operators, defense and dual-use technology firms inside the Thales, Dassault, Safran, MBDA, and Naval Group adjacencies, French fintech, agri-food, energy transition operators, and 7th, 8th, and 16th arrondissement family-office capital. The French heritage signal does not, on its own, place the firm in a US category.
The French business is real. The luxury house carries decades of brand equity and a wholesale and direct-to-consumer footprint that runs through Tokyo, Hong Kong, Dubai, Riyadh, and Shanghai with the heritage reading as a category. The biotech operator has phase-three data and an EMA dossier built to European HTA standards. The defense firm sits inside a Thales, Dassault, Safran, MBDA, or Naval Group tier-one adjacency with a French and EU procurement track record. The fintech operator has scaled across France and the EU. The family office in the 7th, 8th, or 16th arrondissement is committed to a multi-cycle US allocation routed through a fiduciary architecture that mirrors Geneva and Monaco. A US wholesale channel opens, a US direct-to-consumer launch begins, a US Department of Defense procurement entry advances, a US FDA filing proceeds, a US payer engagement starts, or a portfolio company begins its American commercialisation. The first ninety days do not match the model.
The instinct in Paris is to lead harder with the intellectual frame. More provenance. More design lineage. More artisanal continuity. More references to Polytechnique, HEC, ENA, and the grandes écoles. The instinct is right at home and across luxury Asia and the Gulf, and wrong for the American reader. French commercial culture signals authority through intellectual pedigree, design lineage, and institutional standing. American procurement, US wholesale buyers, and US payers read those same signals as quality flags and as cultural sophistication. They do not read them as a US category, a US peer set, or a US-procurement risk architecture. The Made in France premium carries on the shelf in luxury and reads thin in biotech, defense, fintech, and industrial procurement.
American buyers sort fast on three signals: category anchor, outcome claim, and US peer set. Paris materials lead with heritage, design, or intellectual frame and tend to omit the US category entirely. The work is to translate the French identity into a US-legible commercial position without removing what carries at home and across Asia and the Gulf.
The American buyer is not asking for less heritage and not asking for less intellectual frame. They are asking for the US category, the US peer set, and the US-procurement risk architecture that sits underneath the Made in France stamp. House view on Paris to US entry
The design is not the problem. The science is not the problem. The engineering is not the problem. The heritage is not the problem. The American-facing architecture is.
The peer European financial-and-luxury capital comparison to Paris. London-anchored operators rebuilding for US visibility through an Anglophone channel that shares the US sorting habits more closely than Paris does.
See London corridor →The wider Anglophone European market gate. Operators in the UK and Ireland entering US markets. The closest peer market for Paris principals routing US entry through a London-anchored parent, partner, or holding company.
See the UK and Ireland gate →Sprint, Build, and Partnership shapes. Which engagement fits a Paris luxury house, biotech operator, defense firm, fintech, or family-office US rebuild.
See engagements →Six to ten weeks. Single US category, single corridor. The firm rebuilds positioning, pricing posture, messaging, and trust architecture for the American buyer, then launches it into market.
See the Sprint →Three to six months. Multi-channel US rebuild and run. Paid, owned, earned, conversion architecture, and sales enablement. The standard shape for Paris principals committed to US scale.
See the Build →Monthly retainer, twelve-month minimum. Ongoing rebuild-and-run across multiple US surfaces. Typical for Paris luxury houses with US wholesale and direct-to-consumer channels, biotech and defense operators with multi-year US procurement and FDA timelines, and family-office portfolios with several US-facing brands.
See the Partnership →No legal services. No French company formation, no AMF or ACPR notifications, no Banque de France filings, no US entity formation. No L-1, E-2, EB-5, or O-1 visa work. No US tax structuring, FATCA analysis, or France-US double-tax-treaty review. No customs and tariff classification. No ITAR or EAR clearance work for defense and dual-use operators. No US banking introductions. No fiduciary services. No regulatory licensing. No IP filing. No contract drafting. No FDA, FCC, or DOT clearance work for biotech, fintech, or industrial operators.
These belong with French counsel, notaires, and conseils specialised in US entry, and with US counsel on the American side. The firm works inside the parameters they set. When a marketing decision carries legal, tax, or regulatory implications, the firm flags it and defers before execution.
French commercial culture leads with intellectual prestige, design pedigree, and savoir-faire. The Made in France frame works as a luxury positioning signal in Asia and the Gulf and reads in the United States as a quality flag, not as a US category claim. American procurement, US wholesale buyers, and US co-investors sort fast on US category, US peer set, and US-procurement risk architecture. Paris materials lead with intellectual or design pedigree and tend to omit the US category. Paris firms entering the US must put US category, US peer set, and US-procurement risk architecture in the lead with the French heritage carrying as supporting proof.
French luxury houses inside and adjacent to LVMH, Kering, Hermès, Chanel, and Dior, both family-controlled and publicly listed, French biotech and pharma operators including Sanofi, Servier, Ipsen, and BioMérieux adjacencies, French defense and dual-use technology firms inside and around Thales, Dassault Aviation, Safran tier-1, MBDA, and Naval Group adjacencies, French fintech operators including Worldline-adjacent, Ledger, Younited, and Qonto, French agri-food and food technology firms, French infrastructure and energy transition operators inside and around Veolia, Suez, EDF-adjacent, and Engie, and family-office capital concentrated around the 7th, 8th, and 16th arrondissements. Fit is confirmed in discovery, not in published sector lists.
No. French company formation, AMF and ACPR notifications, Banque de France filings, US LLC or C-corp formation, L-1, E-2, EB-5, and O-1 visa support, transfer pricing, US tax residency, customs and tariff classification, ITAR and EAR review for defense operators, and US banking introductions are handled by the principal's French counsel and US counsel. The firm designs US marketing architecture inside the structure counsel has already put in place.
It does not translate as a category. The American buyer reads Made in France as a quality flag and a luxury heritage signal. They do not read it as a US category, and they do not read it as a peer-set signal in biotech, defense, fintech, or industrial procurement. The work is to define the US category the firm competes in, the US peer set the firm sits inside, the US outcome the firm delivers, and the US-procurement risk architecture, then let the heritage carry behind that frame. Heritage is a benefit, not a position.
With an inquiry through the contact form and a short discovery conversation. The firm runs three engagements: Market Entry Sprint (6 to 10 weeks), Cross-Border Build (3 to 6 months), or Group Partnership (monthly retainer, 12-month minimum). Fit and pricing are confirmed in discovery, not published.
The peer European financial-and-luxury capital comparison to Paris. London-anchored operators rebuilding for US visibility through an Anglophone channel that shares the US sorting habits more closely.
See London corridor →The closest published analysis on translating European HTA dossiers and clinical evidence into US-payer reimbursement architecture and US commercial-payer language. The pattern repeats inside the French biotech cohort.
Read the analysis →Sprint, Build, and Partnership shapes. Which engagement fits a Paris luxury house, biotech operator, defense firm, fintech, or family-office US rebuild.
See engagements →